GSK in the clear

Panadol Osteo pricing statement ambiguous, but not false or misleading: ACCC  The Australian Competition and Consumer Commission has concluded its investigation into whether GlaxoSmithKline (GSK) made misleading statements about a price increase of its Panadol Osteo products. The watchdog adjudged it was “unlikely to establish a contravention of the Australian Consumer Law” had occurred in

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous The truth about eight glasses a day…
Next Safety alert: NSAIDs and miscarriage